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STUDY QUESTION: What is the effect of uterine bathing with sonography gel prior to IVF/ICSI-treatment on live birth rates after fresh
embryo transfer in patients with endometriosis?
SUMMARY ANSWER: After formal interim analysis and premature ending of the trial, no significant difference between uterine bathing
using a pharmacologically neutral sonography gel compared to a sham procedure on live birth rate after fresh embryo transfer in endome-
triosis patients (26.7% vs. 15.4%, relative risk (RR) 1.73, 95% confidence interval (CI) 0.81–3.72; P-value 0.147) could be found, although
the trial was underpowered to draw definite conclusions.
WHAT IS KNOWN ALREADY: Impaired implantation receptivity contributes to reduced clinical pregnancy rates after IVF/ICSI-
treatment in endometriosis patients. Previous studies have suggested a favourable effect of tubal flushing with LipiodolVR on natural
conceptions. This benefit might also be explained by enhancing implantation through endometrial immunomodulation. Although recent
studies showed no beneficial effect of endometrial scratching, the effect of mechanical stress by intrauterine infusion on the endometrium
in endometriosis patients undergoing IVF/ICSI-treatment has not been investigated yet.
STUDY DESIGN, SIZE, DURATION: We performed a multicentre, patient-blinded, randomised controlled trial in which women
were randomly allocated to either a Gel Infusion Sonography (GIS, intervention group) or a sham procedure (control group) prior to
IVF/ICSI-treatment. Since recruitment was slow and completion of the study was considered unfeasible, the study was halted after
inclusion of 112 of the planned 184 women.
PARTICIPANTS/MATERIALS, SETTING, METHODS: We included infertile women with surgically confirmed endometriosis
ASRM stage I–IV undergoing IVF/ICSI-treatment. After informed consent, women were randomised to GIS with intrauterine instillation of
ExEm-gelVR or sonography with gel into the vagina (sham). This was performed in the cycle preceding the embryo transfer, on the day
GnRH analogue treatment was started. The primary endpoint was live birth rate after fresh embryo transfer. Analysis was performed by
both intention-to-treat and per-protocol.
VC The Author(s) 2020. Published by Oxford University Press on behalf of European Society of Human Reproduction and Embryology.
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MAIN RESULTS AND THE ROLE OF CHANCE: Between July 2014 to September 2018, we randomly allocated 112 women to
GIS (n¼ 60) or sham procedure (n¼ 52). The live birth rate after fresh embryo transfer was 16/60 (26.7%) after GIS versus 8/52 (15.4%)
after the sham (RR 1.73, 95% CI 0.81–3.72; P-value 0.147). Ongoing pregnancy rate was 16/60 (26.7%) after GIS versus 9/52 (17.3%)
in the controls (RR 1.54, 95% CI 0.74–3.18). Miscarriage occurred in 1/60 (1.7%) after GIS versus 5/52 (9.6%) in the controls (RR 0.17,
95% CI 0.02–1.44) women. Uterine bathing resulted in a higher pain score compared with a sham procedure (visual analogue scale score
2.7 [1.3–3.5] vs. 1.0 [0.0–2.0], P< 0.001). There were two adverse events after GIS compared with none after sham procedures.
LIMITATIONS, REASONS FOR CAUTION: The study was terminated prematurely due to slow recruitment and trial fatigue.
Therefore, the trial is underpowered to draw definite conclusions regarding the effect of uterine bathing with sonography gel on live birth
rate after fresh embryo transfer in endometriosis patients undergoing IVF/ICSI-treatment.
WIDER IMPLICATIONS OF THE FINDINGS: We could not demonstrate a favourable effect of uterine bathing procedures with
sonography gel prior to IVF/ICSI-treatment in patients with endometriosis.
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Introduction
In patients with endometriosis, pregnancy and live birth rates after IVF
or ICSI treatment are reduced compared to patients without endome-
triosis (Barnhart et al., 2002; Harb et al., 2013; Muteshi et al., 2018).
This could be caused by a decreased quality of oocytes, a reduced
implantation capacity of the embryo and/or a diminished endometrial
receptivity (Pellicer et al., 2001; Brosens et al., 2012; Lessey and Kim,
2017). Suggested explanations for the impaired endometrial receptivity
of endometriosis patients undergoing IVF/ICSI-treatment are proges-
terone resistance, inflammation and inadequate decidualisation as well
as the presence of concomitant adenomyosis (Brosens et al., 2012;
Revel, 2012; Vercellini et al., 2014; Muteshi et al., 2018).
For nearly two decades, it has been hypothesised that applying lo-
cal endometrial injury might induce a beneficial effect on endome-
trial receptivity, especially in patients with recurrent implantation
failure (RIF) after IVF/ICSI-treatment (Barash et al., 2003; Zhou
et al., 2008, Potdar et al., 2012; Nastri et al., 2015). Although multi-
ple randomised controlled trials (RCTs) have investigated the effect
of endometrial scratching prior to IVF/ICSI-treatment, the actual
role of applying endometrial injury in women undergoing ART
remains unclear (van Hoogenhuijze et al., 2019). A critical assess-
ment of the quality of papers on endometrial scratching suggests
that methodological problems may have biased the results of the
trials (Li et al., 2019).
As an alternative to scratching the endometrium, its receptivity
might be modulated by infusing fluids into the uterine cavity (‘uterine
bathing’). In patients with minimal to mild endometriosis, undergoing
hysterosalpingography with LipiodolVR , an ethiodised oil derived from
poppy seed, showed improved naturally conceived clinical pregnancy
rates post-procedure (Johnson et al., 2004). Although this result is
possibly explained by a flushing effect on the Fallopian tubes, a direct
WHAT DOES THIS MEAN FOR PATIENTS?
In women with endometriosis, pregnancy rates after fertility treatment with IVF/ICSI are reduced. This is probably related to an impaired
implantation receptivity of the endometrium (attachment of a fertilised oocyte to the inner lining of the uterine cavity).
We investigated whether intrauterine infusion of sonography gel prior to IVF/ICSI treatment would have a beneficial effect on live birth
rate after fresh embryo transfer in patients with endometriosis by improving implantation. Participants were randomly allocated to receive
intrauterine infusion with gel or a sham procedure, in which gel was infused into the vagina.
Although the study was stopped prematurely due to slow recruitment and trial fatigue, the researchers could not demonstrate a favour-
able effect of the intervention in comparison to the sham procedure.
























































































(therapeutic) effect on the endometrial receptivity was suggested as
well. This hypothesis is supported by data from a randomised
controlled animal study (Johnson et al., 2005) in which treatment with
LipiodolVR (vs. infusion with saline vs. sham treatment) altered the den-
dritic cell population of the endometrium in mice, suggesting a
Lipiodol-induced favourable uterine immune response. Endometrial
gene transcript regulation during LipiodolVR uterine bathing has also
demonstrated a downregulation of endometrial Osteopontin, a mole-
cule that could be interfering with implantation receptivity in women
with endometriosis (Johnson et al, 2019). In order to investigate the
effectiveness of pre-IVF uterine bathing with LipiodolVR in women with
endometriosis or RIF, the IVF-LUBE trial was performed (Reilly et al.,
2019). The study was, however, not sufficiently powered to show any
difference between the intervention and control arm.
Besides a possible pharmacological mechanism of LipiodolVR , the
favourable effects of uterine bathing could also be explained as the di-
rect result of mechanical stress on the endometrium. In the available
evidence, a control group treated with intrauterine saline or gel was
not included and endometrial biopsies confirming the drug-therapeutic
effect of LipiodolVR were absent. This hypothesis is partly supported by
the observations in limited quality trials that screening hysteroscopy,
using intrauterine infusion, may increase IVF/ICSI pregnancy rates in
some subpopulations (Bosteels et al., 2010; Karayalçin et al., 2012;
Kamath et al., 2019).
In order to investigate the effect of mechanical pressure by intra-
uterine infusion of a pharmacological neutral sonography gel on the
endometrium in endometriosis patients (ASRM I–IV) undergoing IVF/
ICSI treatment, we designed the TUBIE trial (Trial on Uterine Bathing
before IVF/ICSI treatment in patients with Endometriosis). In the
intervention arm of this randomised trial, we performed a Gel Infusion
Sonography (GIS) prior to IVF/ICSI treatment, and in the control arm,
we applied a sham procedure. In both arms, we used ExEm-gelVR ,
a pharmacologically neutral gel, not containing any components
which may enhance endometrial receptivity (Exalto et al., 2007, 2014;
Emanuel et al., 2012).
We hypothesised that in endometriosis patients scheduled for
IVF/ICSI-treatment, uterine bathing with sonography gel would be
superior to a sham procedure in terms of live birth rates after fresh
embryo transfer, through a mechanical pressure mechanism inducing
local injury of the endometrium.
Material and methods
A multicentre, patient-blinded, parallel two-arm RCT was performed
in four centres in the Netherlands and Belgium with special care for
endometriosis. Participating centres were: Amsterdam UMC (Location
VUmc), Amsterdam, the Netherlands; OLVG, Amsterdam, the
Netherlands; Isala, Zwolle, the Netherlands and Ghent University
Hospital, Ghent, Belgium. The study was approved by the institutional
review board of the Amsterdam UMC (Location VUmc); (METC
VUmc reference number: 2013.242). The study had the acronym
TUBIE trial (Trial on Uterine Bathing before IVF-/ICSI-treatment in
patients with Endometriosis) and was registered in the Dutch Trial
Register (NL4025 (NTR4198), 7 October 2013).
Patients
Infertile women aged 18–42 years with surgically confirmed endometri-
osis (American Society of Reproductive Medicine (ASRM), stage I–IV),
scheduled for IVF/ICSI-treatment, were asked to participate by the
investigators before the start of their IVF/ICSI treatment. Women
with known anomalies of the uterus, a malignancy or a pregnancy
were excluded.
Randomisation and allocation
After written informed consent, women were randomly assigned (1:1)
to either a GIS procedure (intervention) or sham procedure (control).
Randomisation was performed without stratification in randomly per-
muted blocks of 2, 4 or 6, using a computer-generated randomisation
list. This randomisation list was rendered by a statistician (P.M.v.d.V).
All study procedures (intervention and control) were performed by
investigators who were not involved in the IVF- or ICSI-treatment.
Patients, IVF clinic staff, embryologists and IVF technicians were
blinded for the outcomes of randomisation i.e. the performed study
procedure and the subsequent IVF/ICSI-treatment.
Interventions
The study procedures (intervention or sham) were performed in the
cycle preceding IVF/ICSI stimulation and embryo transfer, on the day
GnRH analogue treatment was started (van Hoogenhuijze et al., 2019)
according to a standard long agonist protocol. Both procedures were
performed by investigators who were not involved in the IVF/ICSI-
treatment. For the GIS procedure, pharmacologically neutral ExEm-gel
(GynaecologIQ/GISKIT, IQ Medical Ventures BV, Rotterdam, the
Netherlands) was used (Exalto et al., 2014). A flexible catheter was
placed through the internal ostium infusing a maximum amount of
10 ml gel in the uterine cavity. A transvaginal ultrasound, which was
blinded for the patient, was performed immediately after infusing the
gel. After performing the ultrasound, the catheter was removed and
the procedure was ended.
The sham procedure was performed in a similar way to the GIS
procedure with the exception that the tip of the flexible catheter was
placed in the vaginal posterior fornix, in order to avoid unintentional
endometrial injury. After infusing a maximum amount of 10 ml ExEm-
gelVR intravaginally, a transvaginal ultrasound was performed. Again the
ultrasound was blinded for the patient. After performing this, the pro-
cedure was ended by removal of the catheter.
IVF/ICSI procedure
IVF/ICSI treatment procedures were performed by local protocol. In
summary, at baseline (cycle Day 2 or 3), a transvaginal sonography
was performed. Patients started with oral contraceptives on the third
day of the cycle for the total duration of 3 weeks. After 2 weeks, pitu-
itary downregulation by administration of GnRH agonists was started.
GnRH agonists were continued till and including the day of hCG ad-
ministration. Ovarian stimulation was performed according to the
centres local protocol by recombinant FSH or highly purified HMG
(dosage individually determined) and was started on cycle Day 3.
Patients were monitored routinely by a standard protocol, depending
on the follicle growth. Monitoring was continued until the criteria for

























































































(OvitrelleVR ) were met. Oocyte retrieval was carried out 34–37 h after
hCG injection. IVF/ICSI incubation procedures were performed
according to the clinics standard practice. Embryo transfer (2 em-
bryos) was performed 72–120 h after oocyte retrieval. Remaining
good quality embryos were cryopreserved in nitrogen vapour tanks or
in liquid nitrogen. Luteal support was accomplished by two capsules of
100 mg Utrogestan per vaginam, three times a day, for 15 days, or in
case of pregnancy, 22 days. All medication was registered and mar-
keted in the Netherlands and Belgium.
Outcomes
The primary outcome was live birth rate after fresh embryo transfer.
Secondary outcomes were biochemical pregnancy (increase in serum
hCG), clinical pregnancy (gestational sac, with or without heartbeat, visi-
ble on ultrasound), ongoing pregnancy (viable intrauterine pregnancy
that progresses beyond 12 weeks of gestation), multiple pregnancy (two
or more gestational sacs, with or without heartbeat, visible on ultra-
sound), miscarriage (the presence of non-vitality on ultrasound or spon-
taneous loss of pregnancy before 12 weeks of gestation) and ectopic
pregnancy (defined histologically if treated surgically or by clinical diagno-
sis if managed conservatively), all after the first cycle. If a pregnancy was
terminated (medical-assisted termination of pregnancy before 24 weeks
of gestation), this was reported separately and not counted as live birth.
Furthermore, adverse events of the procedure (such as infection and
bleeding), pain experienced during the procedure (recorded using the vi-
sual analogue scale (VAS 0.0–10.0 cm)) and complications of the
IVF/ICSI treatment, as well as complications during the pregnancy and
postpartum period, and neonatal outcomes were registered.
Sample size
The sample size calculation was based on the data of the interim
analysis of the IVF-LUBE trial (Reilly et al., 2011). To demonstrate an
absolute difference of 20% in live birth rate between the two groups
(20% in the sham group vs. 40% in the GIS group) with a two-sided
significance level of 5% and a power of 80%, 164 patients needed to
be included in this trial. Considering a 10% loss to follow-up, the trial
needed to include 92 patients per study group (184 patients in total).
Statistical analysis
The chi-square test or the Fishers’ exact test was used to compare di-
chotomous outcomes between the two arms of the trial. The relative
risk (RR) is calculated as the effect size together with its 95% confi-
dence interval (CI). The Student’s t-test or Mann–Whitney U test
(depending on the data distribution) was used to compare continuous
outcomes between the arms. All statistics on primary and secondary
outcomes were undertaken for the intention-to-treat (ITT) and per-
protocol (PP) analysis. The statistical analysis was performed in IBM
SPSS Statistics version 22.0 using a two-sided significance level of 5%.
Because of the slow accrual of this trial and the IVF-LUBE trial con-
cluding that uterine bathing with LipiodolVR did not add to the success
of IVF (Reilly et al., 2019), it was decided to perform an interim analy-
sis as soon as half of the planned study population had completed the
study protocol. Details of the interim analysis were added to the trial
protocol and approved by the institutional review board of the
Amsterdam UMC (Location VUmc) before the required data became
available. The interim analysis consisted of calculation of the condi-
tional power which was defined as the probability of concluding live
birth rate to be significantly higher in the GIS arm at the end of the
trial given the planned sample size of 184 patients and the data ob-
served so far. The conditional power was calculated under the as-
sumption that the live birth rates in future participants in each of the
two arms equalled those observed in the participants already included
in the interim analysis. An independent statistician, who had no further
involvement in the trial, performed the interim analysis as unblinding
was considered necessary in order to avoid continuing the trial in case
live birth rate was considerably smaller in GIS arm.
Results
Between July 2014 and September 2018, when the interim analysis was
performed, a total of 113 women were included in this trial. After ran-
domisation, one patient was excluded from the trial as she did not meet
the inclusion criteria (Fergusson et al., 2002). She underwent a short
stimulation IVF/ICSI protocol instead of the long stimulation protocol.
This trial started as a single-centre study in Amsterdam. From the
start, recruitment of participants was progressing slowly. Fewer women
than initially expected fulfilled the in- and exclusion criteria of the study.
This resulted in an adaptation of the inclusion criteria allowing all ASRM
stages of endometriosis to be included (amendment to protocol ap-
proved by institutional review board of the Amsterdam UMC (Location
VUmc)). Unfortunately, this was not enough to reach a sufficient num-
ber of inclusions and lead to engaging collaboration with three other
large endometriosis care centres in the Netherlands and Belgium.
However, even with this expansion, the inclusion rate remained slow,
therefore it was decided to perform an interim analysis where condi-
tional power would be used to decide on continuing or stopping the
trial. At the time of interim analysis, the live birth rate was 24%
(12/49) in the GIS group compared to 19% (8/43) in the sham group.
Conditional power in case of continuing the trial was calculated as 4%.
The conditional power was considered too low to warrant continuation
of the trial and the trial was stopped for futility. Consequently,
112 women allocated to either uterine bathing by GIS (n¼ 60) or a
sham procedure (n¼ 52) were included in the final analysis (Fig. 1).
Baseline characteristics
Baseline characteristics are shown in Table I. In all participants, endo-
metriosis was surgically confirmed: 65 women (58%) were diagnosed
with minimal to mild endometriosis (ASRM stage I–II), 47 women
(42%) with moderate to severe endometriosis (ASRM stage III–IV).
Besides endometriosis, 52 couples (46.6%) had concomitant reasons
for infertility: male factor (total motile sperm count <1  106 ml,
n¼ 27 (24.1%)), tubal factor (one- or two-sided, n¼ 23 (20.5%)),
anovulation (n¼ 7 (6.3%)) and cervical factor (n¼ 2 (1.8%)). Seven
couples (6.3%) had more than two reasons for infertility.
Of the women randomised for GIS, one participant cancelled the
procedure and did not receive the allocated treatment. In the sham
group, one procedure failed as gel was infused into the uterine cavity
during the procedure. Of the 59 women who underwent a GIS proce-
dure, 12 did not undergo fresh embryo transfer after completing the
IVF/ICSI-treatment, including 5 with a poor response, 4 with a hyper


















response or 2 women with total fertilisation failure. In the group with
the sham procedure, five women had a poor response and one a hy-
per response resulting in a cancelled fresh embryo transfer. As a re-
sult, 48/60 women (80%) in the GIS group and 45/52 women
(86.5%) in sham procedure group underwent a fresh embryo transfer.
There was no loss to follow-up.
Pain scores
The median pain scores, measured by VAS (0.0–10.0 cm) directly after
the procedure, were significantly higher following GIS 2.7 cm (25th to
75th percentiles 1.3–3.5) than following the sham procedure 1.0 cm
(0.0–2.0, P< 0.001). There were two adverse events after a GIS pro-
cedure. One woman fainted during the procedure because of exces-
sive pain (VAS 10.0 cm), another woman suffered from non-severe
vaginal blood loss for a day after the procedure (Table II).
IVF/ICSI-treatment
The IVF- or ICSI-treatment characteristics are presented in Table III.
There were no significant differences between the groups. Six women
randomised for a GIS procedure had a complication of the IVF/ICSI-
Assessed for eligibility (n=211) 
Excluded (n=98)
Declined to parcipate (n=98)
Analyzed for ITT analysis (n=52)
Analyzed for PP analysis (n=45)
Underwent fresh embryo transfer (n=45)
Completed follow-up (n=45)
Loss to follow-up (n=0)
Allocated to sham (n=52)
Received allocated intervenon (n=51)
Did not receive allocated intervenon (n=1)
- Failed procedure
Underwent fresh embryo transfer (n=48)
Completed follow-up (n=48)
Loss to follow-up (n=0)
Allocated to GIS (n=60)
Received allocated intervenon (n=59)
Did not receive allocated intervenon (n=1)
- Parcipant cancelled procedure
Analyzed for ITT analysis (n=60)
Analyzed for PP analysis (n=48)
Randomized (n=113)
Excluded (n=1)
Did not meet inclusion criteria (n=1)
Started IVF/ICSI treatment (n=51)
Underwent fresh embryo transfer (n=45)
Did not undergo fresh embryo transfer (n=7)
- Escape IUI (n=3)
- Freeze all due to OHSS (n=1)
- Poor response (n=1)
- Treatment cancelled (n=1)
- GIS procedure performed (n=1)
Started IVF/ICSI treatment (n=59)
Underwent fresh embryo transfer (n=48)
Did not undergo fresh embryo transfer (n=12)
- Escape IUI (n=5)
- Freeze all due to OHSS (n=4)





















Figure 1. Consort flowchart TUBIE trial. GIS, Gel Infusion Sonography; OHSS, ovarian hyperstimulation syndrome; TFF, total fertilisation fail-

























































































treatment: four women were diagnosed with mild-to-moderate
ovarian hyperstimulation syndrome (OHSS) (Navot and Bergh, 1993);
one woman was diagnosed with an ectopic pregnancy for which a
laparoscopic tubotomy was undertaken; and one woman was diag-
nosed with an ovarian torsion in pregnancy at 6 weeks and 6 days of
gestation then underwent a laparoscopy and the pregnancy continued
successfully. In the sham group, only one woman had a complication




The primary outcome, live birth rate per patient, was 16/60 (26.7%)
in the GIS groups compared to 8/52 (15.4%) in the sham group (RR
1.73, 95% CI 0.81–3.72, P¼ 0.147) (Table IV). Secondary outcome
measures are listed in Table IV. Adjustment for baseline characteristics
(ethnicity, antral follicle count, duration infertility and cycle number)
had no impact on the results (not reported). Two sensitivity analyses
were performed: a first sensitivity analysis in which the excluded pa-
tient (n¼ 1) was included in the analysis and a second sensitivity analy-
sis in which we counted the woman in the control group who had her
pregnancy terminated because of trisomy 21 as live birth. Conclusion
of the ITT analysis remained unchanged for both the sensitivity
analyses.
PP analysis
When analysed PP, live birth rate after fresh embryo transfer in the
GIS group was 16/48 (33.3%) versus 8/45 (17.8%) (RR 1.80, 95% CI
0.84–3.82, P-value 0.117). Secondary outcome measures of the PP
analysis are shown in Table V.
Pregnancy, postpartum and neonatal
outcomes
Pregnancy outcomes and postpartum period are shown in Table VI.
One woman in the control group had her pregnancy terminated be-
cause of trisomy 21. In the intervention group, five pregnancy compli-
cations were reported: two women developed hypothyroidism; two
women were diagnosed with gestational diabetes and a placenta previa
and one woman was diagnosed with pre-eclampsia. In the sham group,
two complications of pregnancy were reported: one woman had ges-
tational diabetes and one woman with fetomaternal transfusion. There
were four postpartum complications in the intervention group: three
postpartum haemorrhage and one bladder lesion during caesarean sec-
tion; and one woman in the sham group had a postpartum curettage
because of retained products of conception. There was no significant
difference in neonatal outcomes between the groups. In the interven-
tion group, one child was admitted to the neonatal intensive care unit
because of respiratory distress syndrome after premature birth.
Discussion
The TUBIE trial investigated the effect of uterine bathing using ExEm-
gelVR on live birth rates after fresh embryo transfer in endometriosis
patients undergoing IVF/ICSI-treatment. Regarding the primary out-
come, no significant differences were found between patients rando-
mised for intervention and sham procedures (26.7% vs. 15.4%, RR
1.73, 95% CI 0.81–3.72; P-value 0.147). The study was terminated
......................................................................................................
Table I Baseline characteristics.
GIS Sham
(n 5 60) (n 5 52)
Age (years), median (IQR) 35 [33–39] 36 [33–38]
BMI (kg/m2), median (IQR) 22.3 [20.2–23.9] 21.6 [20.8–24.2]
Smoking, n (%) 3 (5.0) 1 (1.9)
Ethnicity, n (%)
Caucasian 57 (95.0) 42 (80.8)
Non-Caucasian 3 (5.0) 10 (19.2)
Gravidity, n (%)
0 23 (38.3) 25 (48.1)
1 37 (61.7) 27 (51.9)
Parity, n (%)
0 39 (65.0) 35 (67.3)
1 21 (35.0) 17 (32.7)
Miscarriage in obstetric history, n (%) 22 (36.7) 17 (32.7)
Curettage in obstetric history, n (%) 4 (6.7) 6 (11.5)
EUG in obstetric history, n (%) 2 (3.3) 2 (3.8)
Stage of endometriosis (rASRM), n (%)
Minimal / mild (I/II) 30 (50.0) 35 (67.3)
Moderate / severe (III/IV) 30 (50.0) 17 (32.7)
Average cycle duration (days),
median (IQR)
28 [28–30] 28 [28–30]
Total number of AFC on cycle
Day 2–4, mean (§ SD)
15 § 6 11 § 6
Months of infertility, mean (§ SD) 44.2 § 26.8 35.3 § 18.1
Previous MAR in current child wish,
n (%)
54 (90.0) 48 (92.3)
IVF/ICSI cycle number, median (IQR) 2 [1–2] 1 [1–2]
AFC, antral follicle count; EUG, extra uterine gravidity; GIS, Gel Infusion Sonography;
IQR, interquartile range; MAR, medically assisted reproduction; n, number; rASRM,
revised American Society for Reproductive Medicine; SD, standard deviation.
......................................................................................................
Table II Investigational procedure characteristics.
GIS Sham P-values
(n 5 60) (n 5 52)
Amount gel infused (ml),
median (IQR)
6.0 [5.0–7.0] 5.0 [4.0–5.5] 0.003*
Procedure time (min),
mean (§ SD)
9.3§ 2.7 8.5§ 2.0 0.089
Cervical leakage, n (%) 13 (21.7) n/a –
VAS score (cm),
median (IQR)
2.7 [1.3–3.5] 1.0 [0.0–2.0] <0.001*
Adverse event, n (%) 2 (3.3) 0 (0.0) 0.173
IQR, interquartile range; n, number; n/a, not applicable; SD, standard deviation; VAS,
visual analogue scale.
*P-value < 0.05.






..prematurely after a formal interim analysis was performed when 50%
of the planned study population had completed the study protocol.
The main strength of the TUBIE trial was the patient-blinded rando-
mised controlled study design and the analysis on both ITT and PP
basis. All study procedures (intervention and control) were performed
with a pharmacologically neutral gel by investigators who were not in-
volved in the IVF/ICSI-treatment procedures. Additionally, patients
were blinded for the received treatment, since a sham procedure was
............................................................................................................................................................................................................................
Table III IVF/ICSI-treatment characteristics.
GIS Sham P-values
(n 5 60) (n 5 52)
Treatment type, n (%) 0.286
IVF 42 (70.0) 41 (78.8)
ICSI 18 (30.0) 11 (21.2)
Cycle number, median (IQR) 2 [1–2] 1 [1–2] 0.029*
Endometrial thickness at day of hCG (mm), median (IQR) 3.9 [2.8–5.9] 4.0 [2.9–5.3] 0.751
Dose FSH (U), median (IQR) 2225 [1663–2925] 2475 [1650–2925] 0.460
Semen, gain after processing (*106), median (IQR) 14.0 [4.5–49] 20.0 [8.0–49.0] 0.339
Number of retrieved oocytes, median (IQR) 10 [7–14] 8 [5–13] 0.160
Number of fertilised oocytes, median (IQR) 6 [4–8] 5 [3–9] 0.333
Number of embryos for transfer, median (IQR) 5 [4–8] 4 [2–8] 0.333
Number of transferred embryos, n (%) 0.126
No embryo transferred 12 (20) 6 (11.5)
SET 40 (66.7) 43 (82.7)
DET 8 (13.3) 3 (5.8)
Top-quality of transferred embryo, n (%)
Embryo 1 18 (45.0) 17 (39.5) 0.895
Embryo 2 (in case of DET) 2 (25.0) 0 (0.0) 0.338
Blastocyst transfer, n (%) 2 (3.3) 1 (1.9) 0.645
Cryopreservation, n (%) 43 (71.7) 34 (65.4) 0.097
Number of frozen embryos, median (IQR) 4 [2–7] 4 [1–7] 0.277
Complications, n (%) 6 (10.0) 1 (1.9) 0.081
OHSS (mild/moderate) 4 (6.7) 1 (1.9)
Ectopic pregnancy 1 (1.7) 0 (0.0)
Ovarian torsion 1 (1.7) 0 (0.0)
DET, double embryo transfer; GIS, Gel Infusion Sonography; mm, millimetre; n, number; OHSS, ovarian hyperstimulation syndrome; SET, single embryo transfer; U, units.
*P-value < 0.05.
............................................................................................................................................................................................................................
Table IV Primary and secondary outcome measures; pregnancy outcomes after fresh embryo transfer (ITT analysis).
GIS (n 5 60) Sham (n 5 52) P-values Relative risk (RR) 95% CI for the RR
Primary outcome, n (%)
Live birth 16 (26.7) 8 (15.4) 0.147 1.73 (0.81–3.72)
Secondary outcome, n (%)
Biochemical pregnancy 24 (40.0) 18 (34.6) 0.557 1.16 (0.71–1.88)
Clinical pregnancy 17 (28.3) 14 (26.9) 0.868 1.05 (0.58–1.92)
Ongoing pregnancy 16 (26.7) 9 (17.3) 0.236 1.54 (0.74–3.18)
Multiple pregnancy 1 (1.7) 0 (0.0) – – –
Miscarriage 1 (1.7) 5 (9.6) – – –
Ectopic pregnancy 1 (1.7) 0 (0.0) – – –
Termination of pregnancy 0 (0.0) 1 (1.9) – – –






































.performed in the control group. Despite this blinding, it should be
noted that the GIS procedure and sham procedure might have been
experienced differently by the patients, given the fact that the median
pain scores measured immediately after the procedure, were signifi-
cantly higher after GIS compared to that after the sham procedure.
The main weakness was the unplanned interim analysis and the in-
sufficient power of the trial. When initiating the TUBIE trial, we stated
that a 20% improvement in live birth rate in patients receiving GIS pro-
cedure was needed to accept the intervention. However, at the time
of the interim analysis, a 5% improvement was shown in the GIS group
(GIS vs. Sham; 24% vs. 19%). Conditional power in case of continuing
the trial was calculated as 4%, which was considerably less than the
90% which was the preset minimum value for further continuation of
the trial. A high threshold of 90% was chosen and described in an
amendment to protocol, approved by the institutional review board,
because of the considerable trial fatigue which made it only feasible to
continue the trial in case of very promising interim results. It must be
noted that generally much lower thresholds for the conditional power,
around 20–30%, are used to guide stopping for futility. However, also
if a lower threshold for the conditional power was chosen, the trial
would still have been stopped early for futility since the conditional
power at the interim analysis was only 4%.
After terminating the trial, there was a difference of 11.3% in live
birth rate between the groups (26.7% vs. 15.4%). However, this
difference in live birth rate was not statistically significant. Since the
study is underpowered, drawing firm conclusions regarding the effect
of uterine bathing with a pharmacologically neutral gel on live birth
rates after fresh embryo transfer in patients with endometriosis under-
going IVF/ICSI-treatment is impossible. The 20% improvement used in
the original power analysis was based on interim data of the IVF-LUBE
trial (Reilly et al., 2011). In hindsight, this improvement was over-
optimistic.
The idea that local endometrial injury might induce a positive effect
on endometrial receptivity was first suggested by Granot et al. (2000).
Since then, multiple studies have been performed to investigate this ef-
fect, reporting either positive, negative or neutral trial results (Nastri
et al., 2015; Panagiotopoulou et al., 2015). Up until now, a convincing
beneficial effect of endometrial scratching has not been established.
The most recent systematic review still reports high clinical and statisti-
cal heterogeneity in the included trials with no differences between
scratch and controls with respect to live birth and clinical pregnancy
rates (van Hoogenhuijze et al., 2019). In addition, the recently pub-
lished randomised trial of Lensen et al. (2019a) including 1364 women
undergoing endometrial scratching prior to IVF treatment is in line
with these findings and did not report higher live birth rates after
scratching. Among the study population of this trial, 7.9% were endo-
metriosis patients (n¼ 108). Subgroup analysis also showed no benefi-
cial effect of endometrial scratching prior to IVF/ICSI-treatment on
............................................................................................................................................................................................................................
Table V Primary and secondary outcome measures; pregnancy outcomes after fresh embryo transfer (PP analysis).
GIS (n 5 48) Sham (n 5 45) P-values Relative risk (RR) 95% CI for the RR
Primary outcome, n (%)
Live birth 16 (33.3) 8 (17.8) 0.117 1.80 (0.84–3.82)
Secondary outcome, n (%)
Biochemical pregnancy 24 (50) 15 (33) 0.104 1.50 (0.91–2.48)
Clinical pregnancy 17 (35.4) 12 (26.7) 0.363 1.33 (0.72–2.46)
Ongoing pregnancy 16 (33.3) 8 (17.8) 0.087 1.88 (0.89–3.95)
Multiple pregnancy 1 (2.1) 0 (0.0) – – –
Miscarriage 1 (2.1) 4 (8.9) – – –
Ectopic pregnancy 1 (2.1) 0 (0.0) – – –
Termination of pregnancy 0 (0.0) 0 (0.0) – – –
CI, confidence interval; GIS, Gel Infusion Sonography; n, number; PP, per-protocol; RR, relative risk.
............................................................................................................................................................................................................................
Table VI Follow-up of pregnancy and postpartum period.
GIS Sham P-values
(n 5 16) (n 5 8)
Complications during pregnancy, n (%) 5 (31.3) 2 (25.0) 0.750
Postpartum complications, n (%) 4 (25.0) 1 (12.5) 0.477
Gestational age (weeks þ days), median (IQR) 39þ 3 [37þ 6 – 40þ 1] 40þ 0 [37þ 5 – 40þ 2] 0.787
Prematurity, n (%) 1 (6.3) 0 (0.0) –
NICU admittance, n (%) 1 (6.3) 0 (0.0) –
GIS, Gel Infusion Sonography; IQR, interquartile range; n, number; NICU, neonatal intensive care unit.
























































































live birth rate in the endometriosis patients as well. Although endome-
trial scratching is currently the most offered IVF add-on in the UK
(Spencer et al., 2016), the risk of harm should also be considered.
Therefore, this add-on is currently rated as ‘amber’ by the Human
Fertilisation and Embryology Authority (HFEA) (Lensen et al., 2019b).
Theoretically, local injury of the endometrium might also be applied
by infusion of intrauterine fluids or gels. Since previous studies have
suggested that uterine bathing with LipiodolVR might have an effect on
endometrial receptivity by immunomodulation (Johnson et al., 2005;
Johnson, 2014; Johnson et al., 2019), we aimed to investigate the effect
of mechanical stress on the endometrium by uterine bathing with an
pharmacologically neutral non-embryotoxic gel (ExEm-gelVR ). ExEm-gelVR
is frequently used during fertility work-up and is registered and mar-
keted in the Netherlands for GIS procedures (Exalto et al., 2014). To
the best of our knowledge, ExEm-gelVR does not contain potential ther-
apeutic components which may enhance endometrial receptivity
(Exalto et al., 2007, 2014; Emanuel et al., 2012). And although obser-
vations in limited quality trials suggest that screening hysteroscopy
might improve IVF/ICSI-treatment results (Bosteels et al., 2010;
Karayalçin et al., 2012; Kamath et al., 2019), performing uterine bath-
ing with ExEm-gelVR is not endorsed by our study results. This is in ac-
cordance to the final report of the LUBE trial (Reilly et al., 2019) in
which no difference in success rates for IVF following uterine bathing
with Lipiodol for women with endometriosis or RIF could be found.
The trail of Salehpour et al. (2016) in which intrauterine saline infusion
as a form of endometrial injury was performed during IVF treatment
even showed a negative effect on clinical pregnancy numbers and im-
plantation rates among patients with RIF.
The recent insights that applying endometrial injury does not posi-
tively affect reproductive outcomes in patients undergoing IVF/ICSI-
treatment is supported by the results of our TUBIE trial. Overall, the
biological plausibility of performing endometrial injury procedures to
improve endometrial receptivity can be questioned (Simón and
Bellver, 2014). The various hypotheses that might explain the beneficial
effect of applying endometrial injury have never been shown nor
proven by a plausible biological influence on the endometrium and its
effect on implantation. Evidence is derived from trials with high clinical
and statistical heterogeneity and the investigated procedures (scratch-
ing, uterine bathing and screening hysteroscopy) have injured the en-
dometrium in different ways. Additionally, methodological issues are
common in the majority of RCTs reporting on endometrial scratching,
leading to biased trial results (Li et al., 2019). Therefore the results
cannot simply be merged and compared together in a straight forward
way. Furthermore, these invasive procedures can be painful and may
lead to adverse events.
Conclusion
In conclusion, in this prematurely terminated and therefore underpow-
ered multicentre RCT, we found no favourable effect of uterine bath-
ing using a pharmacologically neutral gel compared to a sham
procedure prior to IVF or ICSI treatment on live birth rates after fresh
embryo transfer in patients with endometriosis. Uterine bathing proce-
dures were associated with higher pain scores and a small number of
adverse events. Therefore, uterine bathing procedures are not advised
as a routine add-on to IVF/ICSI treatment in women with
endometriosis.
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